Pluristem Therapeutics Inc (PSTI)

[FDApproved]

The U.S. Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI) is to undertake a pilot study in nonhuman primates (NHP) evaluating Pluristem Therapeutics’ PLX-R18 as a treatment for acute radiation syndrome (ARS) prior to and within the first 24 hours of radiation exposure. The AFRRI is part of the Uniformed Services University of Health Sciences (USUHS).



http://www.genengnews.com/gen-news-highlights/us-dod-to-start-new-trial-with-pluristems-plx-r18-cell-therapy-against-ars/81254818